Literature DB >> 28591537

Blinatumomab for Acute Lymphoblastic Leukemia.

Hagop Kantarjian1, Elias Jabbour1, Max S Topp2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28591537     DOI： 10.1056/NEJMc1704012

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Immunotherapy in Older Adults with Cancer.

Authors:  Richard Curtis Godby; Douglas B Johnson; Grant R Williams
Journal:  Curr Oncol Rep       Date:  2019-05-07       Impact factor: 5.075

2.  Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Authors:  Amy K Keating; Nathan Gossai; Christine L Phillips; Kelly Maloney; Kristen Campbell; Andrew Doan; Deepa Bhojwani; Michael J Burke; Michael R Verneris
Journal:  Blood Adv       Date:  2019-07-09

Review 3.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Authors:  Haifa Shen; Tong Sun; Hanh H Hoang; Jana S Burchfield; Gillian F Hamilton; Elizabeth A Mittendorf; Mauro Ferrari
Journal:  Semin Immunol       Date:  2017-09-23       Impact factor: 11.130

4.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

5.  Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.

Authors:  Vera Dufner; Cyrus M Sayehli; Manik Chatterjee; Horst D Hummel; Götz Gelbrich; Ralf C Bargou; Maria-Elisabeth Goebeler
Journal:  Blood Adv       Date:  2019-08-27

6.  Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.

Authors:  Hetty E Carraway; Yazeed Sawalha; Ivana Gojo; Min-Jung Lee; Sunmin Lee; Yusuke Tomita; Akira Yuno; Jackie Greer; B Douglas Smith; Keith W Pratz; Mark J Levis; Steven D Gore; Nilanjan Ghosh; Amy Dezern; Amanda L Blackford; Maria R Baer; Lia Gore; Richard Piekarz; Jane B Trepel; Judith E Karp
Journal:  Leuk Res       Date:  2021-09-10       Impact factor: 3.156

Review 7.  How mRNA therapeutics are entering the monoclonal antibody field.

Authors:  Lien Van Hoecke; Kenny Roose
Journal:  J Transl Med       Date:  2019-02-22       Impact factor: 5.531

Review 8.  Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.

Authors:  Bingshan Liu; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2017-12-01       Impact factor: 17.388

Review 9.  The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.

Authors:  Eleonora Calabretta; Carmelo Carlo-Stella
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600

10.  A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.

Authors:  Yuexian Zhou; Huifang Zong; Lei Han; Yueqing Xie; Hua Jiang; John Gilly; Baohong Zhang; Huili Lu; Jie Chen; Rui Sun; Zhidi Pan; Jianwei Zhu
Journal:  J Exp Clin Cancer Res       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.